AKT1 and renal fibrosis: Our study shows that TGF-β1 stimulates ERK and AKT signaling channels and promotes renal tubular interstitial fibrosis, and anlotinib is used to reduce the inflammatory response, delay EMT, and improve renal fibrosis by inhibiting TGF-β1.